Wealthfront buys 16,529 Biogen shares as EPS beats estimates
Wealthfront Advisers LLC acquired 16,529 Biogen shares valued at about $3.57M. Deutsche Bank added a new stake worth about $193.17M and other funds increased holdings as well. Biogen reported $3.60 EPS, topping the $2.94 consensus, with revenue up 3.4% year over year, and analysts mostly maintained Buy ratings.